|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
| METASTATIC CASTRATION RESISTANT PROSTATE CANCER |
|
 |
|
|
Finding the Full Spectrum of Genetic Variants in Advanced Prostate Cancer - Rosalind Eeles
|
| In this conversation, Alicia Morgans and Rosalind Eeles discuss how patients should be selected for genetic counseling and testing. This discussion highlights several important questions including: What is the spectrum of genetic predisposition that we currently know? How should we use this?
|
|
|
|
|
|
|
|
|
 |
|
|
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
|
| Professor of Medicine Oliver Sartor from Tulane University joins Charles Ryan to discuss several lutetium studies, radioligand therapy, and the VISION trial and where the state of lutetium currently stands both in the United States and globally with radiopharmaceutical treatment options.
|
|
|
|
|
|
|
|
|
 |
|
| Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer |
|
Bertrand Tombal, MD, Ph.D
|
| Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coexistence of AR-dependent and AR-independent tumor clones.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
| ARCHES: Efficacy of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-sensitive Prostate Cancer
|
| Andrew J. Armstrong, MD, MSc
|
| The introduction of androgen-axis targeted therapies has drastically altered the landscape of advanced prostate cancer. Abiraterone acetate (AA) and enzalutamide have been driving the change, and have been utilized in even earlier stages of advanced prostate cancer. Two recent studies, STAMPEDE, and LATITUDE have established the utility of adding AA + prednisone to ADT among men with high‐risk, hormone‐naïve prostate cancer. |
|
|
|
|
|
| Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy
|
| Silke Gillessen, MD
|
| At the 2019 European Society for Medical Oncology annual meeting (ESMO), experts gathered from urology, radiation oncology, and medical oncology to discuss the clinical management of pelvic node-positive (cN+) prostate cancer. Dr. Silke Gillessen, discussed the role of chemotherapy and androgen receptor targeted therapy (ARTT) in managing pelvic node-positive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Health-Related Quality of Life in a Randomized Phase 3 Trial of Enzalutamide with Standard First Line Therapy for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, ANZUP-led, International, Co-Operative Group Trial |
| Martin R. Stockler, MBBS(Hons) MSc(Clin Epi) FRACP |
| At 2019 ASCO meeting, Davis and colleagues previously reported that treatment with enzalutamide rather than an older non-steroidal anti-androgen (bicalutamide, nilutamide, or flutamide), resulted in longer overall survival when added to standard first-line treatment, with or without concurrent early docetaxel, in mHSPC. Additionally, enzalutamide also leads to longer progression free survival. At the ESMO 2019 prostate cancer session, Dr. Stockler and colleagues from the ENZAMET consortium reported results of the health-related quality of life data. |
|
|
|
|
|
| Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer
|
| Himisha Beltran, MD
|
| Dr. Beltran presented a summary of the biologic basis for sequencing novel treatments for metastatic prostate cancer. There is an increasing need for biomarkers in advanced prostate cancer management – as there is a plethora of treatment options without much guidance about selection or sequencing.
|
|
|
|
|
|
|
